NI 2801
Alternative Names: NI-2801Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Light Chain Bioscience
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Solid-tumours in Switzerland (Parenteral)
- 23 Oct 2020 NI 2801 is available for licensing as of 23 Oct 2020. https://www.lightchainbio.com/
- 23 Oct 2020 Early research in Solid tumours in Switzerland (Parenteral) (Light Chain Bioscience pipeline, October 2020)